Clin2
NCT04895709Possibly a fitRecruiting

Testing a new cancer drug for advanced solid tumors

Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal CancerNon-Small-Cell Lung CancerSquamous Cell Carcinoma of Head and NeckCarcinoma, Renal CellUrothelial CarcinomaPancreatic Adenocarcinoma

Treatments studied

Part of Cancer, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
1,109 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You can provide tumor biopsy samples both before starting and during treatment for lab testing
  • Your cancer must have measurable tumor spots on scans that can be safely biopsied (not bone, fine-needle, or fluid-only samples)
  • Your daily functioning must be fairly good (performance status 0 or 1)
  • Your cancer must have gotten worse on or after your most recent treatment
  • You must have already tried standard treatments, including a relevant PD-(L)1 medicine for your cancer type (if available)
  • You cannot be pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07532902Recruiting· Phase 1
Testing an experimental drug with standard care for solid tumors

This trial tests a new drug (BMS-986504) combined with standard chemotherapy or immunotherapy for three types of advanced solid tumors: mesothelioma, gastroesophageal cancer, or bladder cancer. It may be an option if your tumor has a specific genetic change called MTAP deletion.

Basking Ridge, New Jersey
NCT04999761Recruiting· Phase 1
Study testing new drug combinations for advanced cancers

This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.

Aichi
NCT07160725Recruiting· Phase 1/Phase 2
Testing a new drug for advanced solid tumors

This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.

Irvine, California
NCT06764771Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.

Hackensack, New Jersey
NCT06476808Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.

Los Angeles, California
NCT07223047Recruiting· Phase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes

This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.

Baltimore, Maryland

Hear when a new Cervical Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.